Second Bapineuzumab Trial Fails in Alzheimer’s

Pauline Anderson

A second phase 3 trial investigating bapineuzumab IV in patients with mild to moderate Alzheimer’s disease (AD) has been stopped, essentially spelling the end of the program to investigate this agent in patients with this type of dementia.

The 18-month, randomized, double-blind, multicenter studies were examining the efficacy and safety of bapineuzumab, a monoclonal antibody that targets beta-amyloid (Aß), in patients who carry the apolipoprotein E epsilon 4 (ApoE4) genotype and in those who do not. [Read more…]

Bapineuzumab Fails in Phase 3 Alzheimer’s Trial

Pfizer Inc has announced topline results of a phase 3 trial of bapineuzumab showing treatment failed to meet the co-primary endpoint of change in cognitive or functional performance versus placebo in patients with mild to moderate Alzheimer’s disease (AD) who are positive for the apolipoprotein E4 (ApoE4) risk allele.

Bapineuzumab is an investigational monoclonal antibody that targets amyloid-ß (Aß) under development by the Alzheimer’s Immunotherapy Program (AIP), a partnership between Janssen Alzheimer Immunotherapy R&D LLC (Janssen AI) and Pfizer Inc. [Read more…]